SANUWAVE Health, Inc. filings document a Nevada medical-device company focused on directed-energy systems for advanced wound care and regenerative medicine. Form 8-K reports record results of operations, preliminary financial information, investor presentation materials and material-event disclosures related to the company’s wound care business.
Regulatory filings also cover governance and capital-market disclosure subjects, including annual meeting proxy proposals, director elections, auditor ratification, stockholder advisory votes on executive compensation, officer appointments, compensatory arrangements and separation agreements. Additional filings document accounting matters such as non-reliance on previously issued financial statements connected to historical sales and use tax liabilities.
Form 4 filing snapshot: On 06/30/2025, SANUWAVE Health, Inc. (SNWV) reported a single insider transaction. Chief Executive Officer, Director and 10% owner Morgan C. Frank received a fully-vested stock option for 1,574 common shares at an exercise price of $32.86 per share, expiring 06/30/2030. The filing shows no open-market purchases or sales of common stock, and Mr. Frank now directly holds 1,574 derivative securities. The transaction appears to be routine executive compensation and is unlikely to meaningfully affect the company’s near-term share supply or insider sentiment.
Sanuwave Health (Nasdaq: SNWV) filed an 8-K announcing its 2025 Annual Meeting will be held on August 19, 2025. Stockholders of record at the close of business on July 8, 2025 may vote.
Because no annual meeting occurred in 2024, the company set an accelerated deadline of July 7, 2025 for (1) Rule 14a-8 stockholder proposals, (2) advance-notice director nominations or other business under the bylaws, and (3) universal-proxy notices required by Rule 14a-19. All written submissions must be delivered to the corporate secretary at the Eden Prairie, Minnesota headquarters.
SANUWAVE Health has filed a Form 144 notice indicating a proposed sale of 155,373 shares of common stock with an aggregate market value of $5,058,944.88. The securities were originally acquired on October 18, 2024, through the conversion of convertible notes and warrants into common stock.
Key transaction details:
- Broker: Vanguard Marketing Corporation (El Paso, TX)
- Trading Venue: NASDAQ
- Planned Sale Date: June 25, 2025
- Total Outstanding Shares: 8,555,616
The Form 144 indicates that the seller has no material adverse information about SANUWAVE's operations that hasn't been publicly disclosed. No other securities sales by the same person were reported in the past 3 months. This planned sale represents approximately 1.82% of the company's outstanding shares.